Clinical Trial Update: An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) [Phase 2]

View source ↗

Summary

Extension-phase update for bomedemstat (IMG-7289/MK-3543) in myeloproliferative neoplasms. The Phase 2 extension study in essential thrombocythemia and primary …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis

Drugs mentioned

• Bomedemstat (bomedemstat)

Snippet

Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Conditions: Thrombocythemia, Essential, Primary Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2025-09-22